Uncategorized
Mestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment.
The closing of the financing round, led by life science investors SV Health Investors and Johnson & Johnson Innovation, brings total funds raised to over $95 million.
The funding is set to support the Phase I STARLYS clinical study evaluating MST-0312, which is anticipated to start in cancer patients in mid-2026. MST-0312 is a novel FAP-targeted bispecific antibody directed to lymphotoxin-β receptor (LTBR) to induce the formation of tertiary lymphoid structures (TLS) and high endothelial venules (HEV) within solid tumours.
An extensive body of clinical data correlates the presence of TLS and HEV in solid tumours with improved patient survival and enhanced response to therapy. MST-0312 is a potential first- and best-in-class programme pioneering a new therapeutic approach to the treatment of cancer, including tumours that are typically resistant to immunotherapy.
The announcement comes after Mestag appointed Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer.
“We are thrilled to welcome Lindsey and Pascal to the team at this exciting time as we progress our groundbreaking programme MST-0312 into the STARLYS clinical trial,” said Susan Hill, Chief Executive Officer of Mestag Therapeutics.
The post Mestag raises $40m to advance therapeutic cancer treatment appeared first on Drug Discovery World (DDW).
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Uncategorized
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
Uncategorized
Nonprofit buys experimental cancer drug to maintain patient access
In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.
In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
Nonprofit buys experimental cancer drug to maintain patient access
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
New mRNA Delivery Platform Restores Muscle Function in DMD Models
STAT+: Abridge inks deals with Nvidia and Lilly
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform